Enterprise Value

540.2M

Cash

758.5M

Avg Qtr Burn

-35.92M

Short % of Float

2.47%

Insider Ownership

18.03%

Institutional Own.

75.05%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
obe-cel (AUTO1) (CD19) Details
Acute lymphoblastic leukemia, Cancer, Blood cancer

PDUFA

Approval decision

AUTO4 Details
Peripheral T cell cancer

Phase 1/2

Update

obe-cel (AUTO1) (CD19) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1

Data readout

Phase 1

Data readout

AUTO6NG Details
Solid tumor/s, Neuroblastoma

Phase 1

Update

AUTO1/22 (CD19 & CD22) Details
Acute lymphoblastic leukemia, Cancer, Leukemia

Phase 1

Update

obe-cel (AUTO1) (CD19) Details
Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia

Phase 1

Update

obe-cel (AUTO1) (CD19) Details
Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas

Phase 1

Update

AUTO5 Details
T-cell lymphoma

Phase 1

Initiation

AUTO3 (CD19, CD22) Details
Lymphoma, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued